KetamineOne Announces Two Studies Focused On PTSD, Depression
KetamineOne Capital (NEO: MEDI) has officially begun its research programs. The firm this morning announced the inaugural launch of not one, but two research studies. The studies will be centered around that of PTSD and depression.
The first study, classified as a single arm, open label study of persons with PTSD, will examine persons undergoing what is classified as proprietary physical therapy at the firms IRP Health Clinics. The study, which is to occur over 12 weeks, will study the ability of the program to alleviate pain and PTSD symptoms via exercise therapy, physiotherapy and pain neurophysiology education. The study is said to be observational in nature and will be lead by KGK Science.
The second study will be focused on patients whom suffer from depression that are receiving IV ketamine infusion therapy, with the study looking to collect biometric data and valid psychiatric instrument measures of efficacy of the therapy. The protocol for the study is currently being finalized, with the trial slated to begin late next monh.
Effectively, the latter study will look to provide further data on relapses of depression following ketamine infusion, and to provide further data on the timing of a booster therapy before relapses occur. The study will be conducted at the firms medical clinics.
“The launch of these inaugural studies by Ketamine One is a great milestone for our Company and a clear demonstration of the synergies being created between the subsidiaries of KGK Science and IRP Health. These studies represent full collaboration between all our divisions – KGK, IRP Health and our ketamine clinic network,” commented Adam Deffett, interim CEO of Ketamine One.
KetamineOne Capital last traded at $0.57 on the Neo.
FULL DISCLOSURE: KetamineOne is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover KetamineOne on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
